Delays at MSD’s CMO prompt Sinemet shortage

By Flora Southey contact

- Last updated on GMT

(Image: Getty/wildpixel)
(Image: Getty/wildpixel)

Related tags: Parkinson's disease, MSD, Merck & co

MSD has warned regulators to expect a shortage of its Parkinson’s medicine, Sinemet, due to production constraints at a contract manufacturer’s facility.

MSD (known as Merck & Co. in North America) informed regulatory health agencies in several countries that shortage of two products, Sinemet Plus (25/100) and Sinemet 25/250, are expected from autumn 2018 through to spring, 2019.

MSD outsources the manufacture of Sinemet (carbidopa-levodopa) to an unnamed contract manufacturing organisation (CMO) but packages the drug itself.

According to MSD, supply constraints, coupled with a reduced demand for generic versions of Parkinson’s disease medicines, have prompted the global shortage.

“The manufacturer has recently experienced manufacturing-related delays,” ​MSD told us an emailed statement.

“Historically, generic manufacturers have supplied most of the levodopa, and MSD has provided a small amount of the medicine to the market. Recently, however, supply of this medicine from generic manufacturers has declined, and MSD has received an increase in orders for the product, far exceeding our forecast,” ​the firm added.

MSD expects the shortage to continue until Q1, 2019, but is “working to resolve this situation as quickly as possible”, ​we were told.

Parkinson’s UK’s head of policy and campaigning told us, “This shortage is worrying and we are continuing to work closely with MSD on informing the Parkinson’s community, including healthcare professionals, about it.”

“We are encouraging people with Parkinson’s who are affected to speak to their consultant, Parkinson’s nurse or GP about potential alternatives to the drugs they are currently on. For instance, a generic, non-branded version of Sinemet might be suitable and more readily available,”​ she added.

Related news

Show more

Related products

The battle of performance in pharma production

The battle of performance in pharma production

Telstar Life Science Solutions | 26-Mar-2019 | Case Study

Telstar case study. Discover how a versatile freeze-dryer automatic loading & unloading systemDiscover how a versatile freeze-dryer automatic loading...

Accelerate your supply chain as pressures intensify

Accelerate your supply chain as pressures intensify

William Reed | 17-Sep-2018 | Technical / White Paper

Food, Drink and Non-Food manufacturers are under pressure. Range reviews, massive retail mergers, the backlash against plastic packaging and the ongoing...

Steridose

Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers